In recent years evidence has accumulated that genes involved in circadian clock control play a role as tumor suppressors. Strong evidence has been presented by Broadberry and colleagues who published an article about disrupted circadian clocks in breast cancer (Broadberry et al., 2018[1]). The authors studied primary mammary epithelial cells from normal breast tissue and epithelial cells from breast carcinomas of the same patients. They transduced the cells with the luciferase clock reporter PER2:Luc, which is known to show a robust ~24 h rhythm in normal epithelial cells (Yang et al., 2017[20]). The normal epithelial breast cells showed the expected cycling. However, epithelial cells from the cancer tissue of the same individuals showed a disrupted rhythm with a much lower amplitude (Broadberry et al., 2018[1]). This study confirms previous studies presenting evidence for a tumor suppressor role of the circadian clock (Gery and Koeffler, 2010[7]; Grundy et al., 2013[9]; Fu and Lee, 2003[6]; Mormont and Lévi, 1997[15]; Filipski et al., 2002[5]). Loss of clock genes has been shown to be associated with worse prognosis in breast cancer (Cadenas et al., 2014[3]). Coordinated co-expression of clock genes (e.g. PER2-PER3 and CRY2-PER3) is maintained in estrogen receptor positive and HER2 negative carcinomas but is compromised in more aggressive tumors (Cadenas et al., 2014[3]). Genes relevant for progression of breast carcinomas have been shown to be associated with proliferation (Siggelkow et al., 2012[18]), the cellular and humoral immune system (Schmidt et al., 2008[16], 2012[17]; Heimes et al., 2017[10][11]; Lohr et al., 2013[13]; Godoy et al., 2014[8]), anti-oxidative and anti-apoptotic factors (Hellwig et al., 2016[12]; Cadenas et al., 2010[2]) and altered metabolism (Cadenas et al., 2019[4]; Marchan et al., 2017[14]; Stewart et al., 2012[19]). Although the loss of circadian clock gene expression and its association with tumor prognosis has clearly been shown, the mechanisms of their tumor suppressive effect still need to be elucidated.
Authors: Elisabeth Filipski; Verdun M King; XiaoMei Li; Teresa G Granda; Marie-Christine Mormont; XuHui Liu; Bruno Claustrat; Michael H Hastings; Francis Lévi Journal: J Natl Cancer Inst Date: 2002-05-01 Impact factor: 13.506
Authors: Marcus Schmidt; Birte Hellwig; Seddik Hammad; Amnah Othman; Miriam Lohr; Zonglin Chen; Daniel Boehm; Susanne Gebhard; Ilka Petry; Antje Lebrecht; Cristina Cadenas; Rosemarie Marchan; Joanna D Stewart; Christine Solbach; Lars Holmberg; Karolina Edlund; Hanna Göransson Kultima; Achim Rody; Anders Berglund; Mats Lambe; Anders Isaksson; Johan Botling; Thomas Karn; Volkmar Müller; Aslihan Gerhold-Ay; Christina Cotarelo; Martin Sebastian; Ralf Kronenwett; Hans Bojar; Hans-Anton Lehr; Ugur Sahin; Heinz Koelbl; Mathias Gehrmann; Patrick Micke; Jörg Rahnenführer; Jan G Hengstler Journal: Clin Cancer Res Date: 2012-02-20 Impact factor: 12.531
Authors: Anne Grundy; Johanna M Schuetz; Agnes S Lai; Rozmin Janoo-Gilani; Stephen Leach; Igor Burstyn; Harriet Richardson; Angela Brooks-Wilson; John J Spinelli; Kristan J Aronson Journal: Cancer Epidemiol Date: 2013-05-28 Impact factor: 2.984
Authors: Joanna D Stewart; Rosemarie Marchan; Michaela S Lesjak; Joerg Lambert; Roland Hergenroeder; James K Ellis; Chung-Ho Lau; Hector C Keun; Gerd Schmitz; Juergen Schiller; Mandy Eibisch; Christian Hedberg; Herbert Waldmann; Ekkehart Lausch; Berno Tanner; Jalid Sehouli; Jens Sagemueller; Hagen Staude; Eric Steiner; Jan G Hengstler Journal: Proc Natl Acad Sci U S A Date: 2012-05-08 Impact factor: 11.205
Authors: Birte Hellwig; Katrin Madjar; Karolina Edlund; Rosemarie Marchan; Cristina Cadenas; Anne-Sophie Heimes; Katrin Almstedt; Antje Lebrecht; Isabel Sicking; Marco J Battista; Patrick Micke; Marcus Schmidt; Jan G Hengstler; Jörg Rahnenführer Journal: PLoS One Date: 2016-12-07 Impact factor: 3.240
Authors: Cristina Cadenas; Sonja Vosbeck; Karolina Edlund; Katharina Grgas; Katrin Madjar; Birte Hellwig; Alshaimaa Adawy; Annika Glotzbach; Joanna D Stewart; Michaela S Lesjak; Dennis Franckenstein; Maren Claus; Heiko Hayen; Alexander Schriewer; Kathrin Gianmoena; Sonja Thaler; Marcus Schmidt; Patrick Micke; Fredrik Pontén; Adil Mardinoglu; Cheng Zhang; Heiko U Käfferlein; Carsten Watzl; Saša Frank; Jörg Rahnenführer; Rosemarie Marchan; Jan G Hengstler Journal: Int J Cancer Date: 2019-02-07 Impact factor: 7.396